Hervolution Therapeutics Appoints Biotech Builder J. Robert Coleman As CEO To Accelerate Groundbreaking Immunotherapies To Treat Dark Genome Targets In Cancer, Aging, and Neurodegeneration
Dec 19, 2023•over 1 year ago
Position
Chairman
Company
Hervolution Therapeutics
Description
HERVOLUTION Therapeutics ApS , a pioneering biotechnology company focused on developing novel immunotherapies to treat dark genome targets in cancer, aging, and neurodegeneration, today announces the appointment of J. Robert Coleman, PhD, MBA as its Chief Executive Officer.
Executive Insights
Based on hiring dataNew executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months